NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD
June 14, 2022 11:00 ET
|
NeuroSigma, Inc.
Double-blind randomized controlled trial will enroll up to 225 children at UCLA and Seattle Children’s Hospital NeuroSigma will provide Monarch eTNS Systems and funding for long-term follow-up ...
neurocare group AG continues expansion with opening of first UK clinic in London
June 14, 2022 10:00 ET
|
neurocare group AG
MUNICH, June 14, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...
VAGA Helps People Suffering with Poor Mental Health or Cognitive Decline Through Art Therapy
June 13, 2022 09:00 ET
|
Vaga
New York, June 13, 2022 (GLOBE NEWSWIRE) -- Mental health is a topic that has been under the spotlight in recent years, as people are realising that it is just as important as physical health and...
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
June 02, 2022 14:40 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
New Course from ChildCare Education Institute on Attention Deficit Hyperactivity Disorder
May 26, 2022 03:00 ET
|
ChildCare Education Institute
ATLANTA, GA, May 26, 2022 (GLOBE NEWSWIRE) -- ChildCare Education Institute® (CCEI), an online child care training provider dedicated exclusively to the early care and education workforce, is proud...
Cingulate to Present at H.C. Wainwright Global Investment Conference
May 18, 2022 17:20 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update
May 12, 2022 16:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 12, 2022 08:30 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Cingulate Presents at NobleCon18
April 26, 2022 12:27 ET
|
Cingulate Inc.
KANSAS CITY, Kan., April 26, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug...
NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date
April 07, 2022 11:00 ET
|
NeuroSigma, Inc.
Double-blind randomized controlled trial of eTNS for pediatric ADHD will enroll up to 150 participants at two sites in London and Southampton NeuroSigma’s Monarch eTNS System and electric patches to...